Clinuvel Pharmaceuticals Limited (ASX:CUV)
Australia · Delayed Price · Currency is AUD 9.18
-1.34 (-12.74%)
Aug 27, 2026, 4:10 PM AEST
Clinuvel Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Clinuvel Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $19.63. The average 1-year stock price forecast is 113.83% higher than the current stock price, while the lowest is $9.52 (+3.70%) and the highest is $40.80 (+344.44%).
Price Target: $19.63 (+113.83%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Clinuvel Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Buy Maintains $40.80 | Buy | Maintains | $40.80 | +344.44% | Jul 29, 2026 |
| Bell Potter | Bell Potter | Buy Maintains $19.00 → $17.00 | Buy | Maintains | $19.00 → $17.00 | +85.19% | May 25, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $32.84 → $27.90 | Buy | Maintains | $32.84 → $27.90 | +203.92% | Mar 2, 2026 |
Financial Forecast
Revenue This Year
92.55M
from 101.15M
Decreased by -8.50%
Revenue Next Year
123.97M
from 92.55M
Increased by 33.95%
EPS This Year
0.62
from 0.67
Decreased by -7.34%
EPS Next Year
0.89
from 0.62
Increased by 44.06%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is AUD.